HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Raises Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce maintains a 'Buy' rating on Vera Therapeutics and raises the price target from $10 to $25.
September 26, 2023 | 10:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vera Therapeutics' price target has been raised from $10 to $25 by HC Wainwright & Co. The firm maintains a 'Buy' rating on the stock.
The news of a price target increase and maintained 'Buy' rating by a reputable firm like HC Wainwright & Co. is likely to instill confidence in investors and could lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100